tradingkey.logo

Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial

ReutersJul 8, 2025 11:26 AM

- ProKidney Corp PROK.O:

  • PROKIDNEY REPORTS STATISTICALLY AND CLINICALLY SIGNIFICANT TOPLINE RESULTS FOR THE PHASE 2 REGEN-007 TRIAL EVALUATING RILPARENCEL IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES

  • PROKIDNEY CORP - NO SERIOUS ADVERSE EVENTS OBSERVED WITH RILPARENCEL TREATMENT

  • PROKIDNEY CORP - GROUP 1 SHOWED 78% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCEL

  • PROKIDNEY CORP - GROUP 2 SHOWED 50% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCEL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI